Synonym: 1-[3,5-Bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)-3-piperidinecarboxamide; 1-[3,5-Bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)piperidine-3-carboxamide; CCG 100602; CCG100602
CAS Number: 1207113-88-9
Empirical Formula (Hill Notation): C21H17ClF6N2O2
Molecular Weight: 478.82
Linear Formula: C21H17ClF6N2O2
Product Type: Chemical
assay |
≥98% (HPLC) |
color |
white to beige |
form |
powder |
SMILES string |
O=C(N1CCCC(C(NC2=CC=C(Cl)C=C2)=O)C1)C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3 |
solubility |
DMSO: 2 mg/mL, clear |
storage temp. |
−20°C |
Biochem/physiol Actions: |
CCG-100602 aids in preventing fibrosis around the temporomandibular joint (TMJ). |
Biochem/physiol Actions: |
CCG-100602 is a CCG-1423 analog with significantly less cytotoxicity (0/14% WST-1 inhibition by 10/100 μM CCG-100602 vs. 44% by 10 μM CCG-1423) and similar efficacy against Rho/MKL1/SRF pathway-mediated transcription (by 78% with 100 μM CCG-100602 vs. 74% with 10 μM CCG-1423; IC50 = 9.8 μM/CCG-100602 vs. 1.5 μM/CCG-1423; by PC-3 SRE-luciferase assay), albeit at a reduced potency. CCG-100602 reduces the stiffening of spontaneously hypertensive rats (SHR) derived aortic VSMCs (1.12 μM) by inhibiting SRF/myocardin interaction and abrogates the increased aortic wall stiffness in SHR rats in vivo (7.5 mg/kg/d via s.c. osmotic pumps for 2 wks). |
RIDADR |
NONH for all modes of transport |
WGK Germany |
WGK 3 |
Flash Point(F) |
Not applicable |
Flash Point(C) |
Not applicable |
Purity |
≥98% (HPLC) |
Storage Temp. |
−20°C |
UNSPSC |
12352200 |